Fatigue and its associated factors in ambulatory cancer patients: A preliminary study

被引:76
作者
Akechi, T
Kugaya, A
Okamura, H
Yamawaki, S
Uchitomi, Y
机构
[1] Natl Canc Ctr, Res Inst E, Phychooncol Div, Kashiwa, Chiba 2778577, Japan
[2] Natl Canc Ctr Hosp E, Div Psychiat, Chiba, Japan
[3] Natl Canc Ctr, Dept Psychiat, Tokyo, Japan
[4] Hiroshima Univ, Sch Med, Dept Psychiat & Neurosci, Hiroshima, Japan
关键词
fatigue; cancer; QOL; depression;
D O I
10.1016/S0885-3924(98)00105-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Although fatigue is considered to be one of the major causes of distress among cancer patients, little is known about its association with other factors, such as demographic, medical, and psychosocial factors. A total of 455 ambulatory cancer patients completed the Profile of Mood States (POMS) scale, which includes a fatigue subscale. Other information was obtained in art interview The results of a multiple regression analysis suggested that sex, education, employment status, the size of the household, the performance status, and depressive mood were associated with fatigue. Our findings reveal that the fatigue experienced by cancer patients may be determined by multiple factors, including demographic, physical, and psychological factors. (C) U.S. Cancer Pain Relief Committee, 1998.
引用
收藏
页码:42 / 48
页数:7
相关论文
共 47 条
[1]  
Beisecker AE, 1997, PSYCHO-ONCOL, V6, P85, DOI 10.1002/(SICI)1099-1611(199706)6:2<85::AID-PON247>3.3.CO
[2]  
2-K
[3]   LATE EFFECTS OF ADJUVANT CHEMOTHERAPY AND POSTOPERATIVE RADIOTHERAPY ON QUALITY-OF-LIFE AMONG BREAST-CANCER PATIENTS [J].
BERGLUND, G ;
BOLUND, C ;
FORNANDER, T ;
RUTQVIST, LE ;
SJODEN, PO .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (09) :1075-1081
[4]  
Bruera E, 1988, J Pain Symptom Manage, V3, P9, DOI 10.1016/0885-3924(88)90132-7
[5]  
Bruera E, 1989, J Pain Symptom Manage, V4, P59, DOI 10.1016/0885-3924(89)90023-7
[6]  
BRUERA E, 1990, CANCER, V66, P1279, DOI 10.1002/1097-0142(19900915)66:6&lt
[7]  
1279::AID-CNCR2820660630&gt
[8]  
3.0.CO
[9]  
2-R
[10]  
BRUERA E, 1985, CANCER TREAT REP, V69, P751